Based on numerous studies that demonstrate its broad and significant impact on systemic energy metabolism in response to various metabolic challenges, hepatokine FGF21 holds promise as a potential therapeutic for a wide range of metabolic abnormalities, including obesity and type 2 diabetes [12,13,14,15,176]. The gene discussed is FGF21; the disease is obesity due to melanocortin 4 receptor deficiency.